Hudson Bay Capital Management’s China SXT Pharmaceuticals SXTC Stock Holding History

Hudson Bay Capital Management’s Portfolio SXTC Stock Details SXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1	Closed	-$546K	–	703
2020 Q3	$546K	Hold	1	–	–	0.01%	463
2020 Q2	$1.16M	Hold	1	–	–	0.02%	370
2020 Q1	$1.2M	Hold	1	–	–	0.03%	307
2019 Q4	$1.61M	Hold	1	–	–	0.04%	302
2019 Q3	$2.53M	Hold	1	–	–	0.07%	232
2019 Q2	$6.8M	Buy	+1	New	+$11M	0.16%	136

Other funds holding SXTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Hudock Inc Williamsport, Pennsylvania $680M AUM 18.73% 1-Year Est. Return

Hudson Bay Capital Management's SXTC Position: Q4 2020 in Review

Hudson Bay Capital Management sold out of China SXT Pharmaceuticals (SXTC) in Q4 2020, closing a stake of 1 share — an estimated $546K sold.

Hudson Bay Capital Management first reported a position in SXTC in Q2 2019 and held it in 6 quarters. The position peaked at $6.8M in Q2 2019. 0 funds tracked by Wall St. Rank hold SXTC as of Q4 2020.

Hudson Bay Capital Management reported no remaining China SXT Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Hudson Bay Capital Management sold 1 China SXT Pharmaceuticals share in Q4 2020, an estimated $546K.
Hudson Bay Capital Management first reported a position in China SXT Pharmaceuticals in Q2 2019 and held it in 6 quarters.
Hudson Bay Capital Management's China SXT Pharmaceuticals position peaked at $6.8M in Q2 2019.
0 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q4 2020.

Based on Hudson Bay Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.